DKK 728.0
(2.82%)
Year | Net Income | Net Income Growth |
---|---|---|
2023 | -44.52 Million DKK | -1133.04% |
2022 | 4.31 Million DKK | -93.66% |
2021 | 67.93 Million DKK | 435.28% |
2020 | 12.69 Million DKK | 0.0% |
Year | Net Income | Net Income Growth |
---|---|---|
2024 Q1 | -10.07 Million DKK | 23.66% |
2024 Q2 | -10.07 Million DKK | 0.0% |
2023 Q1 | -9.06 Million DKK | -262.48% |
2023 FY | -44.52 Million DKK | -1133.04% |
2023 Q3 | -13.19 Million DKK | -45.46% |
2023 Q2 | -9.06 Million DKK | 0.0% |
2023 Q4 | -13.19 Million DKK | 0.0% |
2022 Q2 | -3.42 Million DKK | 0.0% |
2022 Q1 | -3.42 Million DKK | 0.0% |
2022 FY | 4.31 Million DKK | -93.66% |
2022 Q3 | 5.58 Million DKK | 262.88% |
2022 Q4 | 5.58 Million DKK | 0.0% |
2021 FY | 67.93 Million DKK | 435.28% |
2020 FY | 12.69 Million DKK | 0.0% |
Name | Net Income | Net Income Difference |
---|---|---|
ALK-Abelló A/S | 486 Million DKK | 109.161% |
Bavarian Nordic A/S | 1.47 Billion DKK | 103.018% |
Genmab A/S | 4.35 Billion DKK | 101.023% |
Novo Nordisk A/S | 83.68 Billion DKK | 100.053% |
Orphazyme A/S | -26.04 Million DKK | -70.931% |
Pharma Equity Group A/S | -24.6 Million DKK | -80.926% |
Zealand Pharma A/S | -703.73 Million DKK | 93.673% |